Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors [Original Articles]

Conclusions— Our analysis suggests that PCSK9 inhibitors are not associated with an increased risk of cumulative severe adverse effects, musculoskeletal effects, or stroke. There is a signal toward adverse neurocognitive effects, seen in the outcome studies with a larger sample size and longer follow-up. There should be close monitoring, for the increased risk of neurocognitive events in the ongoing outcome studies and post-marketing surveillance.

http://circoutcomes.ahajournals.org/cgi/content/short/10/1/e003153?rss=1

Source: Circulation: Cardiovascular Quality and Outcomes - January 9, 2017 Category: Cardiology Authors: Khan, A. R., Bavishi, C., Riaz, H., Farid, T. A., Khan, S., Atlas, M., Hirsch, G., Ikram, S., Bolli, R. Tags: Lipids and Cholesterol, Cardiovascular Disease, Meta Analysis Original Articles Source Type: research